CCR5 blockade modulates inflammation and alloimmunity in primates

Carsten Schröder, Richard N. Pierson, Bao Ngoc H. Nguyen, Douglas W. Kawka, Laurence B. Peterson, Guosheng Wu, Tianshu Zhang, Martin S. Springer, Sal J. Siciliano, Susan Iliff, Julia M. Ayala, Min Lu, John S. Mudgett, Kathy Lyons, Sander G. Mills, Geraldine G. Miller, Irwin I. Singer, Agnes M. Azimzadeh, Julie A. DeMartino

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy in modulating inflammation and immunity is only just beginning to be investigated. In this regard, the recruitment of CCR5-bearing cells into clinical allografts is a hallmark of acute rejection and may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional Δ32 CCR5 receptor rarely exhibit late graft loss. Therefore, we explored the effects of a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model. Although perioperative stress responses (fever, diminished activity) and the recruitment of CCR5-bearing leukocytes into the graft were markedly attenuated, anti-CCR5 monotherapy only marginally prolonged allograft survival. In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppressed cardiac allograft vasculopathy, and tended to further prolong graft survival. CCR5 therefore represents an attractive therapeutic target for attenuating postsurgical stress responses and favorably modulating pathogenic alloimmunity in primates, including man.

Original languageEnglish (US)
Pages (from-to)2289-2299
Number of pages11
JournalJournal of Immunology
Volume179
Issue number4
DOIs
StatePublished - Aug 15 2007

Fingerprint

Primates
Allografts
Inflammation
Transplants
Cyclosporine
Macrophages
CCR5 Receptors
Personnel Selection
Isoantibodies
Macaca fascicularis
Chemokine Receptors
Graft Survival
HIV Infections
Antiviral Agents
Immunity
Leukocytes
Fever
T-Lymphocytes
Kidney
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Schröder, C., Pierson, R. N., Nguyen, B. N. H., Kawka, D. W., Peterson, L. B., Wu, G., ... DeMartino, J. A. (2007). CCR5 blockade modulates inflammation and alloimmunity in primates. Journal of Immunology, 179(4), 2289-2299. https://doi.org/10.4049/jimmunol.179.4.2289

CCR5 blockade modulates inflammation and alloimmunity in primates. / Schröder, Carsten; Pierson, Richard N.; Nguyen, Bao Ngoc H.; Kawka, Douglas W.; Peterson, Laurence B.; Wu, Guosheng; Zhang, Tianshu; Springer, Martin S.; Siciliano, Sal J.; Iliff, Susan; Ayala, Julia M.; Lu, Min; Mudgett, John S.; Lyons, Kathy; Mills, Sander G.; Miller, Geraldine G.; Singer, Irwin I.; Azimzadeh, Agnes M.; DeMartino, Julie A.

In: Journal of Immunology, Vol. 179, No. 4, 15.08.2007, p. 2289-2299.

Research output: Contribution to journalArticle

Schröder, C, Pierson, RN, Nguyen, BNH, Kawka, DW, Peterson, LB, Wu, G, Zhang, T, Springer, MS, Siciliano, SJ, Iliff, S, Ayala, JM, Lu, M, Mudgett, JS, Lyons, K, Mills, SG, Miller, GG, Singer, II, Azimzadeh, AM & DeMartino, JA 2007, 'CCR5 blockade modulates inflammation and alloimmunity in primates', Journal of Immunology, vol. 179, no. 4, pp. 2289-2299. https://doi.org/10.4049/jimmunol.179.4.2289
Schröder C, Pierson RN, Nguyen BNH, Kawka DW, Peterson LB, Wu G et al. CCR5 blockade modulates inflammation and alloimmunity in primates. Journal of Immunology. 2007 Aug 15;179(4):2289-2299. https://doi.org/10.4049/jimmunol.179.4.2289
Schröder, Carsten ; Pierson, Richard N. ; Nguyen, Bao Ngoc H. ; Kawka, Douglas W. ; Peterson, Laurence B. ; Wu, Guosheng ; Zhang, Tianshu ; Springer, Martin S. ; Siciliano, Sal J. ; Iliff, Susan ; Ayala, Julia M. ; Lu, Min ; Mudgett, John S. ; Lyons, Kathy ; Mills, Sander G. ; Miller, Geraldine G. ; Singer, Irwin I. ; Azimzadeh, Agnes M. ; DeMartino, Julie A. / CCR5 blockade modulates inflammation and alloimmunity in primates. In: Journal of Immunology. 2007 ; Vol. 179, No. 4. pp. 2289-2299.
@article{0eadf85660a642978aa216c3e9e14c87,
title = "CCR5 blockade modulates inflammation and alloimmunity in primates",
abstract = "Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy in modulating inflammation and immunity is only just beginning to be investigated. In this regard, the recruitment of CCR5-bearing cells into clinical allografts is a hallmark of acute rejection and may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional Δ32 CCR5 receptor rarely exhibit late graft loss. Therefore, we explored the effects of a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model. Although perioperative stress responses (fever, diminished activity) and the recruitment of CCR5-bearing leukocytes into the graft were markedly attenuated, anti-CCR5 monotherapy only marginally prolonged allograft survival. In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppressed cardiac allograft vasculopathy, and tended to further prolong graft survival. CCR5 therefore represents an attractive therapeutic target for attenuating postsurgical stress responses and favorably modulating pathogenic alloimmunity in primates, including man.",
author = "Carsten Schr{\"o}der and Pierson, {Richard N.} and Nguyen, {Bao Ngoc H.} and Kawka, {Douglas W.} and Peterson, {Laurence B.} and Guosheng Wu and Tianshu Zhang and Springer, {Martin S.} and Siciliano, {Sal J.} and Susan Iliff and Ayala, {Julia M.} and Min Lu and Mudgett, {John S.} and Kathy Lyons and Mills, {Sander G.} and Miller, {Geraldine G.} and Singer, {Irwin I.} and Azimzadeh, {Agnes M.} and DeMartino, {Julie A.}",
year = "2007",
month = "8",
day = "15",
doi = "10.4049/jimmunol.179.4.2289",
language = "English (US)",
volume = "179",
pages = "2289--2299",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - CCR5 blockade modulates inflammation and alloimmunity in primates

AU - Schröder, Carsten

AU - Pierson, Richard N.

AU - Nguyen, Bao Ngoc H.

AU - Kawka, Douglas W.

AU - Peterson, Laurence B.

AU - Wu, Guosheng

AU - Zhang, Tianshu

AU - Springer, Martin S.

AU - Siciliano, Sal J.

AU - Iliff, Susan

AU - Ayala, Julia M.

AU - Lu, Min

AU - Mudgett, John S.

AU - Lyons, Kathy

AU - Mills, Sander G.

AU - Miller, Geraldine G.

AU - Singer, Irwin I.

AU - Azimzadeh, Agnes M.

AU - DeMartino, Julie A.

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy in modulating inflammation and immunity is only just beginning to be investigated. In this regard, the recruitment of CCR5-bearing cells into clinical allografts is a hallmark of acute rejection and may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional Δ32 CCR5 receptor rarely exhibit late graft loss. Therefore, we explored the effects of a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model. Although perioperative stress responses (fever, diminished activity) and the recruitment of CCR5-bearing leukocytes into the graft were markedly attenuated, anti-CCR5 monotherapy only marginally prolonged allograft survival. In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppressed cardiac allograft vasculopathy, and tended to further prolong graft survival. CCR5 therefore represents an attractive therapeutic target for attenuating postsurgical stress responses and favorably modulating pathogenic alloimmunity in primates, including man.

AB - Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy in modulating inflammation and immunity is only just beginning to be investigated. In this regard, the recruitment of CCR5-bearing cells into clinical allografts is a hallmark of acute rejection and may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional Δ32 CCR5 receptor rarely exhibit late graft loss. Therefore, we explored the effects of a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model. Although perioperative stress responses (fever, diminished activity) and the recruitment of CCR5-bearing leukocytes into the graft were markedly attenuated, anti-CCR5 monotherapy only marginally prolonged allograft survival. In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppressed cardiac allograft vasculopathy, and tended to further prolong graft survival. CCR5 therefore represents an attractive therapeutic target for attenuating postsurgical stress responses and favorably modulating pathogenic alloimmunity in primates, including man.

UR - http://www.scopus.com/inward/record.url?scp=34848869334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848869334&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.179.4.2289

DO - 10.4049/jimmunol.179.4.2289

M3 - Article

C2 - 17675490

AN - SCOPUS:34848869334

VL - 179

SP - 2289

EP - 2299

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -